3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 4
3
Phase 2/3
2
Phase 1
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
81
Leukemia
33
Precursor Cell Lymphoblastic Leukemia-Lymphoma
25
Myelodysplastic Syndromes
22
Recurrence
13
Congenital Abnormalities
12
Lymphoma, Non-Hodgkin
9
Leukemia, Biphenotypic, Acute
9
Burkitt Lymphoma
9
Lymphoma, Mantle-Cell
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myelomonocytic, Chronic
7
Leukemia, Monocytic, Acute
7
Hodgkin Disease
7
Lymphoma
6
Leukemia, Myelomonocytic, Acute
6
Leukemia, Megakaryoblastic, Acute
6
Leukemia, Erythroblastic, Acute
6
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Myeloproliferative Disorders
4
Lymphoma, Follicular
4
Lymphoma, B-Cell
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Leukemia, Prolymphocytic
3
Leukemia, Myeloid
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hematologic Neoplasms
3
Blast Crisis
3
Interventions
Cyclophosphamide
4
blinatumomab
3
Azacitidine
3
venetoclax
2
tetrathiomolybdate
1
tagraxofusp
1
siremadlin
1
sabatolimab
1
posaconazole
1
pembrolizumab
1
midostaurin
1
fludarabine phosphate
1
fludarabine
1
daratumumab
1
avelumab
1
aflutinib
1
Whole-Body Irradiation
1
Sirolimus
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Midazolam
1
Melphalan
1
Injections
1
Idarubicin
1
Daunorubicin
1
Cytarabine
1
Celecoxib
1
Capecitabine
1
Biological Assay
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm, Residual
×
Cytarabine
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn